SCHEMBL26631663

SCHEMBL26631663

C[Sn](C)(C)c1ccc(C(F)(F)F)nc1Nc1cccnc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.45
CTSC P53634 1/20 0.42
SYK P43405 6/20 0.39
KDM4E B2RXH2 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PDE5A O76074 2/20 0.38
IL1B P01584 1/20 0.38
NLRP3 Q96P20 1/20 0.38
TSHR P16473 2/20 0.37
RAD52 P43351 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
LCK P06239 1/20 0.36
HDAC4 P56524 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26756689 0.80 KIF11 (0.48) KIF11CTSCSYKKDM4EHSD17B10
SCHEMBL30649421 0.80 KIF11 (0.48) KIF11CTSCSYKKDM4EHSD17B10
SCHEMBL26631696 0.78 IDH1 (0.46) SYKKDM4EHSD17B10PDE5AKMT2A
SCHEMBL26631718 0.77 MAPT (0.39) SYKKMT2A
SCHEMBL30611256 0.75 DHODH (0.48) KIF11SYKKMT2ACYP1A2CYP3A4
SCHEMBL26631670 0.75 MAT2A (0.38) SYKKDM4EKMT2A
SCHEMBL29110282 0.75 KDM4E (0.46) KIF11CTSCSYKKDM4EHSD17B10
SCHEMBL26631710 0.73 CCR4 (0.39) KMT2AHDAC4
SCHEMBL26631653 0.73 LMNA (0.45) KDM4EKMT2ALCKHDAC4
SCHEMBL26631655 0.72 MAT2A (0.40) KDM4EHSD17B10PDE5ATSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A KIF11 1409/4885CTSC 1795/4885SYK 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.